Journal of Marine Biology & Oceanography ISSN: 2324-8661

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Editorial, J Mar Biol Oceanogr Vol: 10 Issue: 4

Approved Drugs from Marine Origin

Emma Griffin*

Editorial Office, Journal of Marine Biology and Oceanography, London, United Kingdom

*Corresponding Author: Emma Griffin Editorial Office Journal of Marine Biology and Oceanography London, United Kingdom E-mail: [email protected]

Received: June 20, 2021 Accepted: June 27, 2021 Published: June 30, 2021

Abstract

Cytarabine is the first anti-cancer medicine of marine origin to be commercially accessible. It's a pyrimidine nucleoside analogue that serves as a cytotoxic medication that targets the cell cycle specifically. It is most active during cell division's S phase, when the cells are undertaking DNA synthesis. The US Food and Drug Administration (FDA) approved cytarabine, which was marketed under the brand name Cytosar-U®. A staple medicine in the treatment of acute myeloid leukaemia, acute lymphoblastic leukaemia, and chronic myelogenous leukaemia is Cytosar-U®. Since then, further anti-cancer compounds derived from marine sources have been accessible. For example, the liposomal formulation CPX-351 (Vyxeos®) contains a 5:1 ratio of cytarabine and daunorubicin. When CPX-351 was delivered to the leukaemia cells of patients with secondary acute myeloid leukaemia, it resulted in a significant improvement in overall survival compared to the standard of care.

Keywords: Cytarabine, Approved Drugs , Marine Origin

Track Your Manuscript